How sphingomyelin metabolism affects lung inflammation from silica exposure
Sphingomyelin Metabolism Impacts on Crystalline Silica-Induced Outcomes
This study is looking at how tiny silica particles can cause long-lasting lung problems and inflammation, and it hopes to find new ways to help people with these issues by understanding how certain cells in the body react to the silica.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Montana NIH-funded |
| Lab location | 1 site (Missoula, United States) |
| Project ID | NIH-10997169 on NIH RePORTER |
What this research studies
This research investigates how exposure to crystalline silica particles can lead to chronic inflammation and lung diseases. It focuses on the role of sphingomyelin metabolism in the process of lysosome membrane permeabilization, which can trigger cell death and inflammation in macrophages. By understanding these mechanisms, the research aims to identify potential new therapies to treat chronic inflammation caused by silica exposure. Patients may benefit from insights that could lead to improved treatment options for lung conditions related to silica and other harmful particles.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been exposed to crystalline silica and are experiencing chronic lung inflammation or related diseases.
Not a fit: Patients who do not have a history of exposure to crystalline silica or similar environmental particles may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel therapies that effectively reduce chronic inflammation and improve lung health for affected patients.
How similar studies have performed: Previous research has shown promising results in understanding inflammation mechanisms related to particle exposure, suggesting that this approach could yield valuable insights.
Where this research is happening
Missoula, United States
- University of Montana — Missoula, United States (Active)
Researchers
- Principal investigator: Albright, Jacob — University of Montana
- Study coordinator: Albright, Jacob
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.